Novartis CEO Vas Narasimhan warned that Trump's MFN drug pricing policy creates a difficult situation, potentially delaying novel medicines in Europe and Japan. This matters as it could lead to reduced access to new treatments for patients in these regions if pharmaceutical companies choose not to launch products there to avoid lowering U.S. prices. Watch for potential delays or cancellations of drug launches in Europe and Japan.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



